☆ 4.6 Article

Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI plus ): Interim analysis of an open-label randomised controlled trial

PLOS MEDICINE (2021)

主要评分表示论文的整体质量水平。次要评分独立反映论文的优点或缺点。

Discuss science. Find collaborators. Network.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started